{
  "asset": "INLEXZO (gemcitabine intravesical system)",
  "query_terms": [
    "INLEXZO (gemcitabine intravesical system)",
    "gemcitabine intravesical system",
    "INLEXZO"
  ],
  "returned_unique": 20,
  "kept": 10,
  "studies": [
    {
      "nct_id": "NCT04658862",
      "title": "A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Urinary Bladder Neoplasms"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Cetrelimab",
        "TAR-200",
        "Cisplatin",
        "Gemcitabine",
        "Conventional radiation therapy",
        "Hypo-fractioned radiation therapy"
      ],
      "last_update": "2025-12-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04658862"
    },
    {
      "nct_id": "NCT06919965",
      "title": "A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)",
      "overall_status": "RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Non-Muscle Invasive Bladder Neoplasms"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "TAR-210",
        "Mitomycin C",
        "Gemcitabine"
      ],
      "last_update": "2025-12-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06919965"
    },
    {
      "nct_id": "NCT04640623",
      "title": "Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin (BCG) Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Urinary Bladder Neoplasms"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "TAR-200",
        "Cetrelimab"
      ],
      "last_update": "2025-12-05",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04640623"
    },
    {
      "nct_id": "NCT04172675",
      "title": "A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions",
      "overall_status": "COMPLETED",
      "phase": "Phase 2",
      "conditions": [
        "Urinary Bladder Neoplasms"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Erdafitinib",
        "Investigator Choice (Gemcitabine)",
        "Investigator Choice (Mitomycin C)"
      ],
      "last_update": "2025-08-01",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04172675"
    },
    {
      "nct_id": "NCT03404791",
      "title": "A Multicenter Study Evaluating Safety and Efficacy of TAR-200 in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy",
      "overall_status": "COMPLETED",
      "phase": "Phase 1",
      "conditions": [
        "Urinary Bladder Neoplasms"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "TAR-200"
      ],
      "last_update": "2025-02-04",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT03404791"
    },
    {
      "nct_id": "NCT07322263",
      "title": "Intravesical Gemcitabine and Docetaxel for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Prospective Cohort Study (GEMDOCE-BU)",
      "overall_status": "NOT_YET_RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Bladder Cancer",
        "Non-Muscle Invasive Bladder Cancer (NMIBC)",
        "Urothelial Carcinoma",
        "Carcinoma in Situ (CIS)",
        "High-Grade Papillary Bladder Tumors",
        "BCG-Unresponsive Bladder Cancer",
        "Ta Stage Bladder Cancer",
        "T1 Stage Bladder Cancer",
        "BCG-Refractory Bladder Cancer",
        "High-Risk NMIBC"
      ],
      "lead_sponsor": "Michael A. O'Donnell",
      "collaborators": [],
      "interventions": [
        "Intravesical Gemcitabine and Docetaxel"
      ],
      "last_update": "2026-01-07",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT07322263"
    },
    {
      "nct_id": "NCT07307456",
      "title": "A Prospective, Open-label, Single-center Clinical Study Evaluating the Efficacy and Safety of Trastuzumab Combined With BCG Perfusion as an Adjuvant Treatment After TURBT in High-risk/Very High-risk Non-muscle-invasive Bladder Cancer",
      "overall_status": "RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Bladder Cancer"
      ],
      "lead_sponsor": "Changhai Hospital",
      "collaborators": [],
      "interventions": [
        "Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor (TURBT)"
      ],
      "last_update": "2025-12-29",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT07307456"
    },
    {
      "nct_id": "NCT06545955",
      "title": "A Phase 3, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)",
      "overall_status": "RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Non-muscle Invasive Bladder Cancer With Carcinoma in Situ"
      ],
      "lead_sponsor": "Ferring Pharmaceuticals",
      "collaborators": [],
      "interventions": [
        "Nadofaragene Firadenovec",
        "Gemcitabine",
        "Docetaxel",
        "Pembrolizumab"
      ],
      "last_update": "2026-01-06",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06545955"
    },
    {
      "nct_id": "NCT07000084",
      "title": "GAIN-BCG: Gemcitabine Alternating With INtravesical BCG Randomized Against BCG Alone for Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer",
      "overall_status": "RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Recurrent Non-Muscle Invasive Bladder Carcinoma",
        "Stage 0a Bladder Cancer AJCC v8",
        "Stage I Bladder Cancer AJCC v8"
      ],
      "lead_sponsor": "Alliance for Clinical Trials in Oncology",
      "collaborators": [
        "National Cancer Institute (NCI)"
      ],
      "interventions": [
        "BCG Solution",
        "Biopsy of Bladder",
        "Cystoscopy",
        "Computed Tomography",
        "Magnetic Resonance Imaging",
        "Biospecimen Collection",
        "Transurethral Resection of Bladder Tumor",
        "Gemcitabine"
      ],
      "last_update": "2026-01-07",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT07000084"
    },
    {
      "nct_id": "NCT05538663",
      "title": "A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)",
      "overall_status": "RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Non-muscle-invasive Bladder Cancer"
      ],
      "lead_sponsor": "ECOG-ACRIN Cancer Research Group",
      "collaborators": [
        "National Cancer Institute (NCI)"
      ],
      "interventions": [
        "Gemcitabine",
        "Docetaxel",
        "Bacillus Calmette Guerin"
      ],
      "last_update": "2025-12-30",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05538663"
    }
  ]
}